-
Product Insights
Spinocerebellar Ataxia (SCA) – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinocerebellar Ataxia (SCA) - Drugs In Development, 2023’, provides an overview of the Spinocerebellar Ataxia (SCA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (SCA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Drugs In Development, 2023’, provides an overview of the Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Retinal Degeneration – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinal Degeneration - Drugs In Development, 2023’, provides an overview of the Retinal Degeneration pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinal Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Fragile X Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Fragile X Syndrome - Drugs In Development, 2023’, provides an overview of the Fragile X Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Thematic Analysis
Digital Transformation and Emerging Technologies in the Healthcare Industry – Thematic Intelligence
Explore trends and insights from the following data in our ‘Digital Transformation and Emerging Technologies in the Healthcare Industry’ report: Stay up to date on the scope, challenges, and essentials for the digital transformation within the healthcare industry. Explore how innovations are transforming the healthcare industry and what impact on the sector these technologies will have soon. Develop and design your corporate strategies through an in-house expert analysis of the key factors of digital transformation and emerging technology in the healthcare sector....
-
Sector Analysis
Artificial Intelligence in Pharma – Impact, Trends, Key Players and Top AI Drugs
This report investigates the impacts and development of Artificial Intelligence within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.
-
Company Insights
Boehringer Ingelheim – Digital Transformation Strategies
Boehringer Digital Transformation Strategies Report Overview Boehringer Ingelheim (Boehringer) is tapping into key disruptive technologies including AI, big data, digital therapeutics, and cloud, among others to enhance its operational efficiency and product offerings. The annual ICT spending of Boehringer is estimated at $1.0 billion for 2022. A major share of this spending is earmarked for acquiring software, ICT services and hardware from vendors. Boehringer is a family-owned pharmaceutical company engaged in the discovery, development, manufacture, and marketing of human pharmaceuticals...
-
Product Insights
Neurofibromatoses Type I (Von Recklinghausen’s Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Neurofibromatosis type 1 (NF1) is also called von Recklinghausen's disease. It is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by a mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules, and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy, and radiation therapy. The NF1 pipeline market research report provides comprehensive information on the therapeutics under development for NF1,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – sulindac
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry sulindac Drug Details Sulindac is under development for the treatment of fragile X syndrome...